Aktana next-best-action suggestions for 600 reps were linked to 14% higher sales among engaged reps within nine months.

Declining HCP access and saturated digital channels cut engagement, and low field adoption limited earlier NBA programmes. Aktana orchestrated suggestions across channels in existing workflows with transparent reasoning, starting with 600 reps across 8 therapeutic areas and 20 brands. The page reports 14% higher sales for engaged reps, $2.5-8M annualised incremental sales and over $30M projected upside with more adoption.

Aktana is a next-best-action and contextual intelligence platform for pharma field teams, now part of PharmaForceIQ, used to guide reps and medical liaisons across channels

This sits in the Scale & Govern stage of the AI use-case lifecycle: Named examples from the tools pharma teams use to monitor, govern and keep validating an AI system once it is already live in production.